Lymph node metastatic patterns of gastric carcinoma with a combination of adenocarcinoma and neuroendocrine carcinoma components

Table 3 Clinicopathological features among lymph node metastasis patterns in adenoneuroendocrine mixed gastric cancer patients who did not undergo neoadjuvant therapy, n (%)

Parameters	NEC	AC	Both	Total	χ2 value	P value
pT stage					5.4	0.045
pT1-2 stage	3 (30)	7 (70)	0 (0)	10 (100)
pT3-4 stage	16 (40)	13 (32.5)	11 (27.5)	40 (100)
LVI					1.6	0.344
-	3 (60)	2 (40)	0 (0)	5 (100)
+	16 (35.6)	18 (40)	11 (24.4)	45 (100)
PNI					1.89	0.396
-	8 (50)	6 (37.5)	2 (12.5)	16 (100)
+	11 (32.4)	14 (41.2)	9 (26.5)	34 (100)
NEC percentage (%)					9.38	0.038
1-29	1 (14.3)	4 (57.1)	2 (28.6)	7 (100)
30-70	8 (27.6)	14 (48.3)	7 (24.1)	29 (100)
71-99	10 (71.4)	2 (14.3)	2 (14.3)	14 (100)
Histology					5.80	0.185
Small cell	9 (52.9)	5 (29.4)	3 (17.6)	17 (100)
Large cell	7 (24.1)	14 (48.3)	8 (27.6)	29 (100)
Both	3 (75)	1 (25)	0 (0)	4 (100)
Lauren type					14.92	0.002
Intestinal type	17 (60.7)	7 (25)	4 (14.3)	28 (100)
Diffuse type	0 (0)	5 (62.5)	3 (37.5)	8 (100)
Mixed type	2 (14.3)	8 (57.1)	4 (28.6)	14 (100)
LN periosteal violation					0.13	1.00
No	6 (40)	6 (40)	3 (20)	15 (100)
Yes	12 (37.5)	13 (40.6)	7 (21.9)	32 (100)
Syn					1.59	1.00
-	0 (0)	1 (100)	0 (0)	1 (100)
+	19 (38.8)	19 (38.8)	11 (22.4)	49 (100)
CgA					2.25	0.298
-	8 (53.3)	4 (26.7)	3 (20)	15 (100)
+	11 (31.4)	16 (45.7)	8 (22.9)	35 (100)
CD56					4.0	0.143
-	2 (18.2)	7 (63.6)	2 (18.2)	11 (100)
+	17 (47.2)	11 (30.6)	8 (22.2)	36 (100)
Sex					0.51	0.865
Female	3 (50)	2 (33.3)	1 (16.7)	6 (100)
Male	16 (36.4)	18 (40.9)	10 (22.7)	44 (100)
Age (year)					3.62	0.494
≤ 45	0 (0)	1 (100)	0 (0)	1 (100)
45-70	16 (44.4)	13 (36.1)	7 (19.5)	36 (100)
≥ 70	3 (23.4)	6 (46.2)	4 (30.7)	13 (100)
Location					4.31	0.116
EGJ	12 (52.2)	6 (26.1)	5 (21.7)	23 (100)
Non-EGJ	7 (25.9)	14 (51.9)	6 (22.2)	27 (100)

NEC: Neuroendocrine carcinoma; AC: Adenocarcinoma; pT: Postoperative pathological tumour; LVI: Lymphatic invasion; PNI: Perineural invasion; LN: Lymph node; Syn: Synaptophysin; CgA: Chromogranin A; CD56: Cluster of differentiation 56; NAC: Neoadjuvant chemotherapy; EGJ: Esophagogastric junction.